Leicester Diabetes Centre, University of Leicester, Leicester, UK.
Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.
Nat Rev Endocrinol. 2021 Jul;17(7):379-380. doi: 10.1038/s41574-021-00495-0.
Cardiometabolic conditions, including type 1 and type 2 diabetes mellitus, are associated with severe COVID-19 and long COVID. Interventions to target multiple risk factors, combined with use of novel glucose-lowering agents that improve metabolic function and the key processes that are impaired in COVID-19, should be the preferred therapeutic options for management of people with long COVID.
心血管代谢疾病，包括 1 型和 2 型糖尿病，与严重的 COVID-19 和长新冠有关。针对多种危险因素的干预措施，加上使用新型降糖药物改善代谢功能和改善 COVID-19 中受损的关键过程，应该是管理长新冠患者的首选治疗选择。
